|
|
|
| Correlation analysis of traditional Chinese medicine syndrome type, lymphocyte subsets, and biochemical indexes of stage Ⅲ/Ⅳ non-small cell lung cancer |
| WANG Fei1 LIU Qiongni1 WANG Jing2 YANG Li1 HU Kaiwen2 ZHOU Tian2 |
1.The Second Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029, China;
2.Department of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China
|
|
|
|
Abstract Objective To explore the correlation between traditional Chinese medicine syndrome type, lymphocyte subsets, and biochemical indexes in patients with stage Ⅲ/Ⅳ non-small cell lung cancer (NSCLC). Methods From November 2020 to February 2022, 153 patients with stage Ⅲ/Ⅳ NSCLC admitted to Dongfang Hospital, Beijing University of Chinese Medicine were selected, including 45 patients with spleen-lung qi deficiency pattern, 33 patients with syndrome of deficiency of lung yin, and 75 patients with syndrome of intermin-gled phlegm and blood stasis. The differences of lymphocyte subsets and biochemical indexes in patients with different traditional Chinese medicine syndrome types were compared. Multiple logistic regression model was used to analyze the correlation between traditional Chinese medicine syndrome types, lymphocyte subsets, and biochemical indexes. Results There were significant differences in CD4+, CD8+, CD4+/CD8+, natural killer cells, total bilirubin, creatinine, and low density lipoprotein-cholesterol among patients with different traditional Chinese medicine syndrome types in stage Ⅲ/Ⅳ NSCLC (P＜0.05). The results of multiple logistic regression model analysis showed that stage Ⅲ/Ⅳ NSCLC patients with spleen-lung qi deficiency pattern compared with syndrome of intermin-gled phlegm and blood stasis, the lower CD4+(OR=0.885, 95%CI: 0.808-0.970), natural killer cells (OR=0.918, 95%CI: 0.850-0.991), and total bilirubin (OR=0.885, 95%CI: 0.814-0.962), the more likely it was spleen-lung qi deficiency pattern (P＜0.05). In stage Ⅲ/Ⅳ NSCLC patients with syndrome of deficiency of lung yin compared with syndrome of intermin-gled phlegm and blood stasis, the lower CD4+ (OR=0.824, 95%CI: 0.733-0.925), the more likely it was syndrome of deficiency of lung yin (P＜0.05). Conclusion The levels of CD4+, natural killer cells, and total bilirubin in patients with stage Ⅱ/Ⅳ NSCLC are related to traditional Chinese medicine syndrome types, which can be used to assist syndrome differentiation.
|
|
|
|
|
|
[1] Oliver AL. Lung Cancer：Epidemiology and Screening [J]. Surg Clin North Am，2022，102（3）：335-344.
[2] Xia C，Dong X，Li H，et al. Cancer statistics in China and United States，2022：profiles，trends，and determinants [J]. Chin Med J（Engl），2022，135（5）：584-590.
[3] Luo J，Yang H，Song BL. Mechanisms and regulation of cho- lesterol homeostasis [J]. Nat Rev Mol Cell Biol，2020，21（4）： 225-245.
[4] Soyano AE，Dholaria B，Marin-Acevedo JA，et al. Peripheral blood biomarkers correlate with outcomes in advanced non- small cell lung Cancer patients treated with anti-PD-1 antibodies [J]. J Immunother Cancer，2018，6（1）：129.
[5] Tanizaki J，Haratani K，Hayashi H，et al. Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab [J]. J Thorac Oncol，2018，13（1）：97-105.
[6] Andrejeva G，Rathmell JC. Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors [J]. Cell Metab，2017，26（1）：49-70.
[7] Lyssiotis CA，Kimmelman AC. Metabolic Interactions in the Tumor Microenvironment [J]. Trends Cell Biol，2017，27（11）： 863-875.
[8] Wang L，Wu W，Zhu X，et al. The Ancient Chinese Decoction Yu-Ping-Feng Suppresses Orthotopic Lewis Lung Cancer Tumor Growth Through Increasing M1 Macrophage Polarization and CD4（+）T Cell Cytotoxicity [J]. Front Pharmacol，2019，10：1333.
[9] Jia W，Wang L. Using Traditional Chinese Medicine to Treat Hepatocellular Carcinoma by Targeting Tumor Immunity [J]. Evid Based Complement Alternat Med，2020，2020：9843486.
[10] 肖真真，朱燕娟，余娅娅，等.热毒宁注射液、参附注射液联合吉非替尼对非小细胞肺癌细胞增殖、干性特征及代谢的影响[J/OL].中国实验方剂学杂志：1-11.https://doi.org/10.13422/j.cnki.syfjx.20222421.
[11] Rami-Porta R，Bolejack V，Giroux DJ，et al. The IASLC lung cancer staging project：the new database to inform the eighth edition of the TNM classification of lung cancer [J]. J Thorac Oncol，2014，9（11）：1618-1624.
[12] Goldstraw P，Chansky K，Crowley J，et al. The IASLC Lung Cancer Staging Project：Proposals for Revision of the TNM Stage Groupings in the Forthcoming（Eighth）Edition of the TNM Classification for Lung Cancer [J]. J Thorac Oncol，2016，11（1）：39-51.
[13] 国家中医药管理局.24个专业92个病种中医诊疗方案[M].北京：国家中医药管理局医政司，2017.
[14] 胡凯文，左明焕，肖俐，等.王沛治疗肺癌用药经验[J].中国中医基础医学杂志，2010，16（9）：783-784，786.
[15] 郗昱檀，马纯政，常思思，等.基于数据挖掘分析全国名老中医治疗肺癌经验及用药规律[J].辽宁中医杂志，2022，49（12）：1-5.
[16] 王怡，孙霃平，秦悦农，等.乳腺术后三阴方对三阴性乳腺癌患者术后健康生活质量的疗效分析[J].中华中医药杂志，2021，36（12）：7483-7488.
[17] 梁健宁，林洁衡，陈燕红，等.金福安汤结合化疗对中晚期非小细胞肺癌老年患者免疫功能及生存质量的影响[J].辽宁中医杂志，2022，49（8）：77-80.
[18] 李艳，范耀华，戴桂萍，等.非小细胞肺癌患者治疗前后外周血淋巴细胞绝对计数的表达差异及与CEA、SCC的相关性[J].广东医学，2022，43（3）：384-387.
[19] 李国玲，王喜英，刘天舟.肺癌患者外周血T细胞亚群检测的临床意义[J].中国冶金工业医学杂志，2000（6）：48.
[20] 吴姗姗.小细胞和非小细胞肺癌晚期患者NK细胞表达的差异[J].中国免疫学杂志，2015，31（2）：250-252，260.
[21] 王慧贤，黄东晖.刘伟胜教授辨证论治肺癌经验[J].西部中医药，2020，33（11）：56-58.
[22] 徐升，徐经世.国医大师徐经世治疗肺癌学术经验[J].山东中医杂志，2018，37（4）：319-321.
[23] 李际强，徐凯，罗翌，等.肺癌患者中医证候分型与T淋巴细胞亚群及NK细胞的相关性研究[J].江西中医学院学报，2007，70（4）：36-39.
[24] 吴姗姗，王柏山，张宁，等.非小细胞肺癌晚期患者常见中医证型淋巴细胞亚群表达的差异[J].中国老年学杂志，2020，40（8）：1618-1621.
[25] 刘宁.刘华为治疗75例肺癌及其他肺病的辨证思路与经验[J].中国民间疗法，2017，25（12）：6-8.
[26] HOrsfall LJ，Burgess S，Hall I，et al. Genetically raised serum bilirubin levels and lung cancer：a cohort study and Mendelian randomisation using UK Biobank [J]. Thorax，2020，75（11）：955-964.
[27] He MM，Fang Z，Hang D，et al. Circulating liver function markers and colorectal cancer risk：A prospective cohort study in the UK Biobank [J]. Int J Cancer，2021，148（8）：1867- 1878.
[28] 朱超林，常宁.奚肇庆运用虫类药治疗肺癌经验拾零[J].辽宁中医杂志，2011，38（10）：1969-1970. |
|
|
|
